Schering-Plough Afrin, Lotrimin GMP Shortcomings Cited In FDA-483 Report
This article was originally published in The Tan Sheet
Executive Summary
Batch validations at a Schering-Plough manufacturing site in Puerto Rico uncovered several problems related to Afrin nasal spray and Lotrimin antifungal, FDA-483 inspection reports show.
You may also be interested in...
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
Schering GMP Criminal Investigation Continues After Consent Decree
Schering-Plough faces a potential criminal case regarding GMP violations after finalizing a consent agreement with FDA May 17
GMP Compliance – Not Investment – Impresses FDA, Chief Counsel Says
Manufacturers should not expect FDA to back off from GMP enforcement actions simply because firms have increased their investment in compliance, FDA Chief Counsel Daniel Troy said during a recent University of Georgia GMP conference